Association of Hemoglobin and Survival in Peritoneal Dialysis Patients

Abstract

SummaryBackground and objectives Interventional trials and some observational studies show target hemoglobin Ͼ13 g/dl to be associated with higher mortality in erythropoiesis-stimulating agent-treated (ESA-treated) hemodialysis patients; data for peritoneal dialysis (PD) patients are limited.Design, setting, participants, & measurements We tested our hypothesis that higher and lower achieved hemoglobin levels are associated with increased mortality in 9269 ESA-treated PD patients from all DaVita dialysis clinics during the time period

Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM‐HD Study

“…Regidor et al15 have reported a U‐shaped curve relationship between hemoglobin and all‐cause mortality in patients undergoing hemodialysis. In contrast, the results of our study were biased toward the left side of the U‐shaped curve, which were similar to those of previous studies on nondialysis and peritoneal dialysis patients with CKD 14, 16. However, the higher the hemoglobin level (>13.5 g/dL) the higher the mortality, as reported by Regidor et al 15.…”

2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

“…The results showed that the survival prognosis was better in patients with Hb levels of ≥11 g/dL, both in diabetic and nondiabetic patients [56]. In 2011, Molnar et al conducted a study of 9269 PD patients and found that survival prognoses and cardiovascular prognoses were most favorable in the patients with Hb levels of 12-13 g/dL [59]. As discussed above, it is difficult to clearly define the target Hb levels in PD patients at this point because the evidence for the appropriate target Hb levels in PD patients is limited.…”

Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced chronic kidney disease

“…tertiles) of eGFR slope groups using KaplanMeier curves and unadjusted conditional Cox regression models. For each PS-matched analysis, several 'doubly robust' adjustment levels can be examined including minimally adjusted and case-mix adjusted models, as well as more comprehensive adjustment such as inclusion of laboratory and comorbidity status, as we have done in our recent studies [33,[56][57][58][59][60][61][62][63]. The PS method can primarily be used to account for confounding effects arising from differences in clinical characteristics of patients in whom transition to RRT occurs at different levels of eGFR.…”